You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


UK bladder cancer patients get early access to Bavencio

Merck and Pfizer’s Bavencio (avelumab) is now available under the UK’s Early Access to Medicines Scheme (EAMS) giving some patients with bladder cancer the chance to receive treatment with the immunotherapy before its approval in Europe.